CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.
The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.
To get more details visit : http://www.researchbeam.com/global-chemotheraphy-induced-nausea-and-vomitting-cinv-drugs-2015-2019-market
Covered in this report
The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.
Technavios report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck and Co
• Tesaro
Other prominent vendors
• Acacia Pharma
• Aphios
• Barr Laboratories
• Baxter Healthcare
• Eisai
• Especificos Stendhal
• F.Hoffmann La Roche
• Mundipharma
• Mylan Pharmaceuticals
• OPKO Health
• Orchid Healthcare
• Otsuka Pharmaceutical
• ProStrakan
• Sandoz (Novartis)
• Solvay Pharmaceuticals
• Specialised Therapeutics Australia
• Sun Pharma
• Taiho Pharmaceutical
• Teva Pharmaceuticals
Market driver
• Increase in incidence and prevalence of cancer
• For a full, detailed list, view our report
Market challenge
• Complex physiology of CINV
• For a full, detailed list, view our report
Market trend
• Increased use of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.
To get more details visit : http://www.researchbeam.com/global-chemotheraphy-induced-nausea-and-vomitting-cinv-drugs-2015-2019-market
Covered in this report
The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.
Technavios report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck and Co
• Tesaro
Other prominent vendors
• Acacia Pharma
• Aphios
• Barr Laboratories
• Baxter Healthcare
• Eisai
• Especificos Stendhal
• F.Hoffmann La Roche
• Mundipharma
• Mylan Pharmaceuticals
• OPKO Health
• Orchid Healthcare
• Otsuka Pharmaceutical
• ProStrakan
• Sandoz (Novartis)
• Solvay Pharmaceuticals
• Specialised Therapeutics Australia
• Sun Pharma
• Taiho Pharmaceutical
• Teva Pharmaceuticals
Market driver
• Increase in incidence and prevalence of cancer
• For a full, detailed list, view our report
Market challenge
• Complex physiology of CINV
• For a full, detailed list, view our report
Market trend
• Increased use of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
No comments:
Post a Comment